LC004496

2022 -- S 2325

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2022

AN ACT

RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES

Introduced By: Senators DiMario, Euer, Miller, Cano, Murray, Lawson, Valverde, Sosnowski, Archambault, and Kallman Date Introduced: February 15, 2022

Referred To: Senate Health & Human Services

It is enacted by the General Assembly as follows:

- 1 SECTION 1. Chapter 27-18 of the General Laws entitled "Accident and Sickness Insurance
- 2 Policies" is hereby amended by adding thereto the following section:
- 3 <u>27-18-89. Over-the-counter COVID-19 tests.</u>
- 4 (a) Every individual or group health insurance contract, plan or policy issued for delivery
- 5 or renewed in this state on or after July 1, 2022, which provides medical coverage that includes
- 6 coverage for physician services in a physician's office, and every policy which provides major
- 7 medical or similar comprehensive-type coverage, shall include coverage for FDA approved over-
- 8 <u>the-counter ("OTC") COVID-19 tests.</u>
- 9 (b) As used in this section, "FDA approved OTC COVID-19 test" means an over-the-
- 10 counter diagnostic test kit that serves to detect active COVID-19 infections and for which the
- 11 United States Food and Drug Administration has issued an authorization. The term includes:
- 12 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain
- 13 reaction (PCR) test, which provides results after a sample is received by a laboratory;
- 14 (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which
- 15 provides results in minutes; and
- 16 (3) Any other OTC test developed in the future that serves to detect active COVID-19 and
- 17 receives FDA authorization.
- 18 (c) Insurers must cover FDA approved OTC COVID-19 tests, including tests obtained
- 19 without involvement of a health care provider. The coverage must be provided without imposing

- 1 any cost-sharing requirements, prior authorization, or other medical management requirements. 2 (d) Insurers shall not limit the number of OTC COVID-19 tests covered for each member to fewer than eight (8) tests per thirty (30) day period or per calendar month. 3 4 (1) Insurers shall not be permitted to limit members to a smaller number of these OTC 5 COVID-19 tests over a shorter period (for example, limiting individuals for two (2) tests per week). 6 (2) Insurers shall count each test separately if multiple tests are sold in one package. 7 (e) To comply with this section, insurers must provide direct coverage for OTC COVID-8 19 tests to members by reimbursing sellers directly without requiring members to provide upfront 9 payment and seek reimbursement. 10 (1) Insurers shall establish a network of pharmacies or retailers online and in convenient 11 locations in Rhode Island, where members will be able to receive tests for free. 12 (2) In providing OTC COVID-19 tests through the direct coverage program, an insurer 13 must take reasonable steps to ensure that members have adequate access to OTC COVID-19 tests, 14 though an adequate number of retail locations, including both in-person and online locations. 15 (3) Insurers shall permit members to elect to purchase OTC COVID-19 tests from other 16 retailers outside the network. In such cases, the insurer shall reimburse the member at least twelve 17 dollars (\$12.00) per individual test (or the cost of the test, if less than twelve dollars (\$12.00)). (f) The direct coverage program shall permit members to obtain OTC COVID-19 tests on 18 19 behalf of other covered members in the same household. 20 (g) OTC COVID-19 tests obtained pursuant to this section shall be for at-home personal 21 use and not for resale. Insurers may act to prevent, detect, and address fraud and abuse through various permissible activities; provided that, such steps do not create significant barriers for 22 23 members to obtain these tests. 24 (h) Insurers shall inform enrollees in writing of the coverage available under this section. 25 (i) The health insurance commissioner shall promulgate any regulations and issue any 26 guidance, as the commissioner deems necessary for the efficient administration and enforcement 27 of this section. 28 (j) Insurers who do not comply with this section shall be considered non-compliant with § 29 27-18-86. 30 (k) This section shall not apply to insurance coverage providing benefits for: 31 (1) Hospital confinement indemnity; 32 (2) Disability income; 33 (3) Accident only;
- 34 <u>(4) Long-term care;</u>

1 (5) Medicare supplement; 2 (6) Limited benefit health; (7) Specified disease indemnity; 3 (8) Sickness or bodily injury or death by accident or both; and 4 5 (9) Other limited benefit policies. SECTION 2. Chapter 27-19 of the General Laws entitled "Nonprofit Hospital Service 6 7 Corporations" is hereby amended by adding thereto the following section: 8 27-19-81. Over-the-counter COVID-19 tests. 9 (a) Every individual or group health insurance contract, plan or policy issued for delivery or renewed in this state on or after July 1, 2022, which provides medical coverage that includes 10 11 coverage for physician services in a physician's office, and every policy which provides major 12 medical or similar comprehensive-type coverage, shall include coverage for FDA approved over-13 the-counter ("OTC") COVID-19 tests. 14 (b) As used in this section, "FDA approved OTC COVID-19 test" means an over-the-15 counter diagnostic test kit that serves to detect active COVID-19 infections and for which the 16 United States Food and Drug Administration has issued an authorization. The term includes: 17 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; 18 19 (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which 20 provides results in minutes; and 21 (3) Any other OTC test developed in the future that serves to detect active COVID-19 and 22 receives FDA authorization. 23 (c) Insurers must cover FDA approved OTC COVID-19 tests, including tests obtained 24 without involvement of a health care provider. The coverage must be provided without imposing 25 any cost-sharing requirements, prior authorization, or other medical management requirements. 26 (d) Insurers shall not limit the number of OTC COVID-19 tests covered for each member 27 to fewer than eight (8) tests per thirty (30) day period or per calendar month. 28 (1) Insurers shall not be permitted to limit members to a smaller number of these OTC 29 COVID-19 tests over a shorter period (for example, limiting individuals for two (2) tests per week). 30 (2) Insurers shall count each test separately if multiple tests are sold in one package. 31 (e) To comply with this section, insurers must provide direct coverage for OTC COVID-32 19 tests to members by reimbursing sellers directly without requiring members to provide upfront 33 payment and seek reimbursement. 34 (1) Insurers shall establish a network of pharmacies or retailers online and in convenient

- 1 locations in Rhode Island, where members will be able to receive tests for free.
- 2 (2) In providing OTC COVID-19 tests through the direct coverage program, an insurer must take reasonable steps to ensure that members have adequate access to OTC COVID-19 tests, 3 4 though an adequate number of retail locations, including both in-person and online locations. 5 (3) Insurers shall permit members to elect to purchase OTC COVID-19 tests from other retailers outside the network. In such cases, the insurer shall reimburse the member at least twelve 6 7 dollars (\$12.00) per individual test (or the cost of the test, if less than twelve dollars (\$12.00)). 8 (f) The direct coverage program shall permit members to obtain OTC COVID-19 tests on 9 behalf of other covered members in the same household. 10 (g) OTC COVID-19 tests obtained pursuant to this section shall be for at-home personal 11 use and not for resale. Insurers may act to prevent, detect, and address fraud and abuse through 12 various permissible activities; provided that, such steps do not create significant barriers for 13 members to obtain these tests. 14 (h) Insurers shall inform enrollees in writing of the coverage available under this section. 15 (i) The health insurance commissioner shall promulgate any regulations and issue any 16 guidance as the commissioner deems necessary for the efficient administration and enforcement of 17 this section. 18 (j) Insurers who do not comply with this section shall be considered non-compliant with § 19 27-19-78. 20 (k) This section shall not apply to insurance coverage providing benefits for: 21 (1) Hospital confinement indemnity; 22 (2) Disability income; 23 (3) Accident only; 24 (4) Long-term care; (5) Medicare supplement; 25 26 (6) Limited benefit health; 27 (7) Specified disease indemnity; 28 (8) Sickness or bodily injury or death by accident or both; and 29 (9) Other limited benefit policies. 30 SECTION 3. Chapter 27-20 of the General Laws entitled "Nonprofit Medical Service 31 Corporations" is hereby amended by adding thereto the following section: 32 27-20-77. Over-the-counter COVID-19 tests. 33 (a) Every individual or group health insurance contract, plan or policy issued for delivery
- 34 or renewed in this state on or after July 1, 2022, which provides medical coverage that includes

- 1 <u>coverage for physician services in a physician's office, and every policy which provides major</u>
- 2 medical or similar comprehensive-type coverage, shall include coverage for FDA approved over-
- 3 the-counter ("OTC") COVID-19 tests.
- 4 (b) As used in this section, FDA approved OTC COVID-19 test means an over-the-counter
- 5 diagnostic test kit that serves to detect active COVID-19 infections and for which the United States
- 6 Food and Drug Administration has issued an authorization. The term includes:
- 7 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain
- 8 reaction (PCR) test, which provides results after a sample is received by a laboratory;
- 9 (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which
- 10 provides results in minutes; and
- 11 (3) Any other OTC test developed in the future that serves to detect active COVID-19 and
- 12 <u>receives FDA authorization.</u>
- 13 (c) Insurers must cover FDA approved OTC COVID-19 tests, including tests obtained
- 14 without involvement of a health care provider. The coverage must be provided without imposing
- 15 <u>any cost-sharing requirements, prior authorization, or other medical management requirements.</u>
- 16 (d) Insurers shall not limit the number of OTC COVID-19 tests covered for each member
- 17 to fewer than eight (8) tests per thirty (30) day period or per calendar month.
- 18 (1) Insurers shall not be permitted to limit members to a smaller number of these OTC
- 19 <u>COVID-19 tests over a shorter period (for example, limiting individuals for two (2) tests per week).</u>
- 20 (2) Insurers shall count each test separately if multiple tests are sold in one package.
- 21 (e) To comply with this section, insurers must provide direct coverage for OTC COVID-
- 22 <u>19 tests to members by reimbursing sellers directly without requiring members to provide upfront</u>
- 23 payment and seek reimbursement.
- 24 (1) Insurers shall establish a network of pharmacies or retailers online and in convenient
- 25 locations in Rhode Island, where members will be able to receive tests for free.
- 26 (2) In providing OTC COVID-19 tests through the direct coverage program, an insurer
- 27 <u>must take reasonable steps to ensure that members have adequate access to OTC COVID-19 tests</u>,
- 28 though an adequate number of retail locations, including both in-person and online locations.
- 29 (3) Insurers shall permit members to elect to purchase OTC COVID-19 tests from other
- 30 retailers outside the network. In such cases, the insurer shall reimburse the member at least twelve
- 31 dollars (\$12.00) per individual test (or the cost of the test, if less than twelve dollars (\$12.00)).
- 32 (f) The direct coverage program shall permit members to obtain OTC COVID-19 tests on
- 33 <u>behalf of other covered members in the same household.</u>
- 34

1	(g) OTC COVID-19 tests obtained pursuant to this section shall be for at-home personal
2	use and not for resale. Insurers may act to prevent, detect, and address fraud and abuse through
3	various permissible activities; provided that, such steps do not create significant barriers for
4	members to obtain these tests.
5	(h) Insurers shall inform enrollees in writing of the coverage available under this section.
6	(i) The health insurance commissioner shall promulgate any regulations and issue any
7	guidance as the commissioner deems necessary for the efficient administration and enforcement of
8	this section.
9	(j) Insurers who do not comply with this section shall be considered non-compliant with §
10	<u>27-20-74.</u>
11	(k) This section shall not apply to insurance coverage providing benefits for:
12	(1) Hospital confinement indemnity;
13	(2) Disability income;
14	(3) Accident only;
15	(4) Long-term care;
16	(5) Medicare supplement:
17	(6) Limited benefit health;
18	(7) Specified disease indemnity:
19	(8) Sickness or bodily injury or death by accident or both; and
20	(9) Other limited benefit policies.
21	SECTION 4. Chapter 27-41 of the General Laws entitled "Health Maintenance
22	Organizations" is hereby amended by adding thereto the following section:
23	27-41-94. Over-the-counter COVID-19 tests.
24	(a) Every individual or group health insurance contract, plan or policy issued for delivery
25	or renewed in this state on or after July 1, 2022, which provides medical coverage that includes
26	coverage for physician services in a physician's office, and every policy which provides major
27	medical or similar comprehensive-type coverage, shall include coverage for FDA approved over-
28	the-counter ("OTC") COVID-19 tests.
29	(b) As used in this section, "FDA approved OTC COVID-19 test" means an over-the-
30	counter diagnostic test kit that serves to detect active COVID-19 infections and for which the
31	United States Food and Drug Administration has issued an authorization. The term includes:
32	(1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain
33	reaction (PCR) test, which provides results after a sample is received by a laboratory;
34	(2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which

1 provides results in minutes; and

2	(3) Any other OTC test developed in the future that serves to detect active COVID-19 and
3	receives FDA authorization.
4	(c) Insurers must cover FDA approved OTC COVID-19 tests, including tests obtained
5	without involvement of a health care provider. The coverage must be provided without imposing
6	any cost-sharing requirements, prior authorization, or other medical management requirements.
7	(d) Insurers shall not limit the number of OTC COVID-19 tests covered for each member
8	to fewer than eight (8) tests per thirty (30) day period or per calendar month.
9	(1) Insurers shall not be permitted to limit members to a smaller number of these OTC
10	COVID-19 tests over a shorter period (for example, limiting individuals for two (2) tests per week).
11	(2) Insurers shall count each test separately if multiple tests are sold in one package.
12	(e) To comply with this section, insurers must provide direct coverage for OTC COVID-
13	19 tests to members by reimbursing sellers directly without requiring members to provide upfront
14	payment and seek reimbursement.
15	(1) Insurers shall establish a network of pharmacies or retailers online and in convenient
16	locations in Rhode Island, where members will be able to receive tests for free.
17	(2) In providing OTC COVID-19 tests through the direct coverage program, an insurer
18	must take reasonable steps to ensure that members have adequate access to OTC COVID-19 tests,
19	though an adequate number of retail locations, including both in-person and online locations.
20	(3) Insurers shall permit members to elect to purchase OTC COVID-19 tests from other
21	retailers outside the network. In such cases, the insurer shall reimburse the member at least twelve
22	dollars (\$12.00) per individual test (or the cost of the test, if less than twelve dollars (\$12.00)).
23	(f) The direct coverage program shall permit members to obtain OTC COVID-19 tests on
24	behalf of other covered members in the same household.
25	(g) OTC COVID-19 tests obtained pursuant to this section shall be for at-home personal
26	use and not for resale. Insurers may act to prevent, detect, and address fraud and abuse through
27	various permissible activities; provided that, such steps do not create significant barriers for
28	members to obtain these tests.
29	(h) Insurers shall inform enrollees in writing of the coverage available under this section.
30	(i) The health insurance commissioner shall promulgate any regulations and issue any
31	guidance as the commissioner deems necessary for the efficient administration and enforcement of
32	this section.
33	(j) Insurers who do not comply with this section shall be considered non-compliant with §
34	<u>27-41-91.</u>

1	(k) This section shall not apply to insurance coverage providing benefits for:
2	(1) Hospital confinement indemnity;
3	(2) Disability income:
4	(3) Accident only;
5	(4) Long-term care;
6	(5) Medicare supplement;
7	(6) Limited benefit health;
8	(7) Specified disease indemnity;
9	(8) Sickness or bodily injury or death by accident or both; and
10	(9) Other limited benefit policies.
11	SECTION 5. Chapter 42-7.2 of the General Laws entitled "Office of Health and Human
12	Services" is hereby amended by adding thereto the following section:
13	42-7.2-21. Over-the-counter COVID-19 tests.
14	(a) Rhode Island Medicaid and its contracted managed care entities shall provide coverage
15	for FDA approved over-the-counter (OTC) COVID-19 tests through the pharmacy benefit.
16	(b) As used in this section, FDA approved OTC COVID-19 test means an over-the-counter
17	diagnostic test kit that serves to detect active COVID-19 infections and for which the United States
18	Food and Drug Administration has issued an authorization. The term includes:
18 19	Food and Drug Administration has issued an authorization. The term includes: (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain
19	(1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain
19 20	(1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory;
19 20 21	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which
19 20 21 22	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and
 19 20 21 22 23 	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and (3) Any other OTC test developed in the future that serves to detect active COVID-19 and
 19 20 21 22 23 24 	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and (3) Any other OTC test developed in the future that serves to detect active COVID-19 and receives FDA authorization.
 19 20 21 22 23 24 25 	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and (3) Any other OTC test developed in the future that serves to detect active COVID-19 and receives FDA authorization. (c) Rhode Island Medicaid and its contracted managed care entities must cover FDA
 19 20 21 22 23 24 25 26 	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and (3) Any other OTC test developed in the future that serves to detect active COVID-19 and receives FDA authorization. (c) Rhode Island Medicaid and its contracted managed care entities must cover FDA approved OTC COVID-19 tests, including tests obtained without involvement of a health care
 19 20 21 22 23 24 25 26 27 	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and (3) Any other OTC test developed in the future that serves to detect active COVID-19 and receives FDA authorization. (c) Rhode Island Medicaid and its contracted managed care entities must cover FDA approved OTC COVID-19 tests, including tests obtained without involvement of a health care provider. The coverage must be provided without imposing any cost-sharing requirements, prior
 19 20 21 22 23 24 25 26 27 28 	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and (3) Any other OTC test developed in the future that serves to detect active COVID-19 and receives FDA authorization. (c) Rhode Island Medicaid and its contracted managed care entities must cover FDA approved OTC COVID-19 tests, including tests obtained without involvement of a health care provider. The coverage must be provided without imposing any cost-sharing requirements, prior authorization, or other medical management requirements.
 19 20 21 22 23 24 25 26 27 28 29 	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and (3) Any other OTC test developed in the future that serves to detect active COVID-19 and receives FDA authorization. (c) Rhode Island Medicaid and its contracted managed care entities must cover FDA approved OTC COVID-19 tests, including tests obtained without involvement of a health care provider. The coverage must be provided without imposing any cost-sharing requirements, prior authorization, or other medical management requirements. (d) Rhode Island Medicaid and its contracted managed care entities shall not limit the
 19 20 21 22 23 24 25 26 27 28 29 30 	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and (3) Any other OTC test developed in the future that serves to detect active COVID-19 and receives FDA authorization. (c) Rhode Island Medicaid and its contracted managed care entities must cover FDA approved OTC COVID-19 tests, including tests obtained without involvement of a health care provider. The coverage must be provided without imposing any cost-sharing requirements, prior authorization, or other medical management requirements. (d) Rhode Island Medicaid and its contracted managed care entities shall not limit the number of OTC COVID-19 tests covered for each member to fewer than eight (8) tests per thirty
 19 20 21 22 23 24 25 26 27 28 29 30 31 	 (1) A COVID-19 self-collection kit, including, but not limited to, a polymerase chain reaction (PCR) test, which provides results after a sample is received by a laboratory; (2) A COVID-19 self-test kit, including, but not limited to, a rapid antigen test, which provides results in minutes; and (3) Any other OTC test developed in the future that serves to detect active COVID-19 and receives FDA authorization. (c) Rhode Island Medicaid and its contracted managed care entities must cover FDA approved OTC COVID-19 tests, including tests obtained without involvement of a health care provider. The coverage must be provided without imposing any cost-sharing requirements, prior authorization, or other medical management requirements. (d) Rhode Island Medicaid and its contracted managed care entities shall not limit the number of OTC COVID-19 tests covered for each member to fewer than eight (8) tests per thirty (30) day period or per calendar month.

- 1 (2) Rhode Island Medicaid and its contracted managed care entities shall count each test 2
- separately if multiple tests are sold in one package.
- 3 (e) To comply with this section, Rhode Island Medicaid and its contracted managed care
- 4 entities must provide direct coverage for OTC COVID-19 tests to members by reimbursing sellers
- 5 directly without requiring members to provide upfront payment and seek reimbursement.
- 6 (1) Rhode Island Medicaid and its contracted managed care entities shall establish a
- 7 network of pharmacies or retailers online and in convenient locations in Rhode Island, where
- 8 members will be able to receive tests for free.
- 9 (2) In providing OTC COVID-19 tests through the direct coverage program, Rhode Island
- 10 Medicaid and its contracted managed care entities must take reasonable steps to ensure that
- 11 members have adequate access to OTC COVID-19 tests, though an adequate number of retail
- 12 locations, including both in-person and online locations.
- 13 (3) Rhode Island Medicaid and its contracted managed care entities shall permit members
- 14 to elect to purchase OTC COVID-19 tests from other retailers outside the network. In such cases,
- 15 Rhode Island Medicaid and its contracted managed care entities shall reimburse the member at least
- 16 twelve dollars (\$12.00) per individual test (or the cost of the test, if less than twelve dollars
- 17 (\$12.00)).
- 18 (f) The direct coverage program shall permit members to obtain OTC COVID-19 tests on
- 19 behalf of other covered members in the same household.
- (g) OTC COVID-19 tests obtained pursuant to this section shall be for at-home personal 20
- 21 use and not for resale. Rhode Island Medicaid and its contracted managed care entities may act to
- 22 prevent, detect, and address fraud and abuse through various permissible activities; provided that,
- 23 such steps do not create significant barriers for members to obtain these tests.
- 24 (h) Rhode Island Medicaid and its contracted managed care entities shall inform enrollees
- in writing of the coverage available under this section. 25
- 26 (i) The secretary shall promulgate any regulations and issue any guidance as the secretary
- 27 deems necessary for the efficient administration and enforcement of this section.
- 28 SECTION 6. This act shall take effect on January 1, 2023.

LC004496

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

AN ACT

RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES

- 1 This act would mandate that health insurance companies and Medicaid provide coverage
- 2 for FDA approved COVID-19 home testing kits.
- 3 This act would take effect on January 1, 2023.

LC004496